Second-line therapy after VEGF targeted therapy in metastatic renal cancer: A law of diminishing returns

Clinical Genitourinary Cancer

Volumn 10, Issue 2, 2012, Pages 67-68

  Powles, Thomas ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AXITINIB; EVEROLIMUS; SORAFENIB;

ALOPECIA; ANEMIA; CANCER SURVIVAL; CLEAR CELL CARCINOMA; DISEASE COURSE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG TOLERABILITY; DYSPHONIA; EDITORIAL; FATIGUE; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; HYPOTHYROIDISM; KIDNEY CANCER; LOW DRUG DOSE; METASTATIC RENAL CANCER; MOLECULARLY TARGETED THERAPY; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; SINGLE NUCLEOTIDE POLYMORPHISM; SOLID TUMOR; SURVIVAL RATE; TISSUE SECTION;

ANGIOGENESIS INHIBITORS; BENZENESULFONATES; CARCINOMA, RENAL CELL; CLINICAL TRIALS AS TOPIC; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; HUMANS; IMIDAZOLES; INDAZOLES; KIDNEY NEOPLASMS; MOLECULAR TARGETED THERAPY; PYRIDINES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84862084888     PISSN: 15587673     EISSN: 19380682     Source Type: Journal    
DOI: 10.1016/j.clgc.2012.04.001     Document Type: Editorial

References (9)

1. B. Rini, B. Escudier, P. Tomczak Axitinib versus sorafenib as second-line therapy for metastatic renal cell carcinoma (mRCC): results of phase III AXIS trial J Clin Oncol 29 Suppl 2011 Abstract 4503
2. R.J. Motzer, B. Escudier, S. Oudard Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors Cancer 116 2010 4256 4265
3. I. Kayani, N. Avril, J. Bomanji Sequential FDG-PET/CT as a biomarker of response to sunitinib in metastatic clear cell renal cancer Clin Cancer Res 17 2011 6021 6028
4. J.M. Ebos, C.R. Lee, W. Cruz-Munoz Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis Cancer Cell 15 2009 232 239
5. O. Rixe, R.M. Bukowski, M.D. Michaelson Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study Lancet Oncol 8 2007 975 984 (Pubitemid 47629888)
6. D. Cella, B. Escudier, B. Rini Patient-reported outcomes (PROs) in a phase III AXIS trial of axitinib versus sorafenib as second-line therapy for metastatic renal cell carcinoma (mRCC) J Clin Oncol 29 Suppl 2011 Abstract 4504
7. R.J. Motzer, T.E. Hutson, P. Tomczak Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma J Clin Oncol 27 2009 3584 3590
8. F. Schutz, K. Gray, M. Pomerantz Choueiri T do genetic polymorphisms predict risk of recurrence in patients with localized renal cell carcinoma? Results from a cohort study J Clin Oncol 29 Suppl 2011 Abstract 4506
9. B.I. Rini, M.D. Michaelson, J.E. Rosenberg Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma J Clin Oncol 26 2008 3743 3748